Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full ...

Therapeutics aims to improve current obesity treatment, specifically to increase overall body weight loss and fat mass loss, but p ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

I’ m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’ m wondering about Ozempic. I’ m also hearing about people doing Ozempic microdosing.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Chia seeds have emerged as a popular superfood due to their nutritional benefits, aiding in hunger management, digestion, and ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

GLP-1 medications are making headlines in medical weight loss—learn how they impact overall health and chronic disease ...

GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...

Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide in people with obesity or overweight and type 2 diabetes led to a 15.7% ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.